As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is critical for policymakers to understand the potential solutions.

This brief describes Kaiser Permanente’s approach to providing high-quality, unbiased information to prescribers.

Drug Policy 101: Kaiser Permanente’s Approach to Drug Detailing

Watch Dr. Maisha Draves, MD, MPH, Medical Director of Pharmacy, describe Kaiser Permanente’s approach

Other papers in this series:

• Pay-for-delay
• FDA risk evaluation and mitigation strategy (REMS)
• Biosimilars
• Patents
• The state of the pharmaceutical evidence base